Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Medicenna Therapeutics Corp. has enhanced its Board of Directors by appointing Karim Lalji, a seasoned life sciences strategist with a history of fostering significant pharmaceutical partnerships and driving substantial company growth. Lalji’s previous experience includes a transformative licensing deal for Cardiome Pharma and leadership roles at Merck & Company, contributing to his extensive industry expertise. Excited about joining Medicenna, Lalji recognizes the company’s potential for advancing immune-based therapies with its promising Superkine platform.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
